Pharmacokinetic Difference of Six Active Constituents of Huangqi Liuyi Decoction between Control and Diabetic Nephropathy Mouse Models.
Qun WangYa ShiXingde LiuTing LiuYongjun LiXinli SongXiaolan ChenYang JinWen LiuYonglin WangZi-Peng GongPublished in: International journal of analytical chemistry (2022)
Huangqi Liuyi decoction is a famous traditional Chinese medicine (TCM) that has been widely used in China for the management of diabetes since the Song Dynasty. Today, it is commonly used for treating diabetic nephropathy (DN). Our previous experimental studies have suggested that the mixture HQD, containing astragalus saponin, astragalus flavone, astragalus polysaccharide, and glycyrrhetinic acid, could be used for the treatment of DN and to improve renal function. The objective of this study was to develop a sensitive and reliable high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of astragaloside IV, calycosin-7-O- β -D-glucoside, calycosin-glucuronide, ononin, formononetin, and glycyrrhizic acid, which are the main active constituents in HQD, and to compare the pharmacokinetics of these active constituents in control and DN mice orally treated with HQD. The results indicated that the pharmacokinetic parameters of HQD were significantly different between the control and DN mouse groups. The absorption of HQD in the DN mice was greater than that in control mice.
Keyphrases
- diabetic nephropathy
- liquid chromatography tandem mass spectrometry
- high fat diet induced
- simultaneous determination
- ms ms
- type diabetes
- cardiovascular disease
- mouse model
- solid phase extraction
- skeletal muscle
- insulin resistance
- high performance liquid chromatography
- tandem mass spectrometry
- combination therapy
- liquid chromatography